期刊
CANCER RESEARCH
卷 76, 期 1, 页码 73-82出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-1707
关键词
-
类别
资金
- NIH [R21 AI114255, R21 CA190044, P50 CA086306]
- California Institute for Regenerative Medicine (CIRM) [RT1-01126-1]
- UCLA Scholars in Oncologic Molecular Imaging training program [NIH R25T CA098010]
- CIRM Training Grant [TG2-01169]
- UCLA In vivo Cellular and Molecular Imaging Center Career Development Award [P50 CA086306]
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
- Dr. Robert Vigen Memorial Fund
- Ressler Family Foundation
- UCLA Jonsson Comprehensive Cancer Center [NIH CA016042]
- [P01 CA168585]
The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of noninvasive and quantitative technologies capable of monitoring the presence and abundance of CD8(+) T cells and other immune cell subsets. In this study, we describe the generation of Zr-89-desferrioxamine-labeled anti-CD8 cys-diabody (Zr-89-malDFO-169 cDb) for noninvasive immuno-PET tracking of endogenous CD8(+) T cells. We demonstrate that anti-CD8 immuno-PET is a sensitive tool for detecting changes in systemic and tumor-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including antigen-specific adoptive T-cell transfer, agonistic antibody therapy (anti-CD137/4-1BB), and checkpoint blockade antibody therapy (anti-PD-L1). The ability of anti-CD8 immuno-PET to provide whole body information regarding therapy-induced alterations of this dynamic T-cell population provides new opportunities to evaluate antitumor immune responses of immunotherapies currently being evaluated in the clinic. (C)2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据